Therapeutic approach guided by genetic alteration: Use of MTOR inhibitor in renal medullary carcinoma with loss of PTEN expression

Renal Medullary Cancer (RMC) is a rare and aggressive type of renal cell cancer that presents predominantly in patients with sickle cell hemoglobinopathies, and is typically metastatic at the time of presentation. Although platinum based chemotherapeutic regimens have recently emerged as the best op...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipkin, Jacob S, Rizvi, Syed M, Gatalica, Zoran, Sarwani, Nabeel E, Holder, Sheldon L, Kaag, Mathew, Drabick, Joseph J, Joshi, Monika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2015
Materias:
Bedside to Bench Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622500/
https://www.ncbi.nlm.nih.gov/pubmed/25692619
http://dx.doi.org/10.4161/15384047.2014.972843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622500/
https://www.ncbi.nlm.nih.gov/pubmed/25692619
http://dx.doi.org/10.4161/15384047.2014.972843

Ejemplares similares